Erythropoietin Pretreatment Exerts Anti-Inflammatory Effects in Hepatic Ischemia/Reperfusion-Injured Rats Via Suppression of the TLR2/NF-kappa B Pathway

摘要

Introduction. The inflammatory response plays an important role in liver dysfunction after hepatic ischemia/reperfusion (I/R), which is tightly regulated by the Toll-like receptor 2 (TLR2)uclear factor (NF)-kappa B pathway; suppression of TLR2/NF-kappa B signaling has therefore become a promising target for anti-inflammatory treatment in hepatic I/R injury. Erythropoietin (EPO) is a glycoprotein cytokine produced primarily by the kidney that has anti-inflammatory activities. The purpose of the present study was to investigate the effect of EPO preconditioning, if any, against hepatic I/R injury in rats and its underlying mechanisms.